Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A [TRX-1] in Patients With Rheumatoid Arthritis

Next Previous
X
Search
Trial Profile

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A [TRX-1] in Patients With Rheumatoid Arthritis

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TRX 1-Tolerx (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Genentech

    • Most Recent Events

    • 06 Mar 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 06 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Aug 2010 Results presented at the 11th Annual Congress of the European League Against Rheumatism in June 2010.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top